Quemliclustat named orphan drug by FDA for pancreatic cancer

Quemliclustat named orphan drug by FDA for pancreatic cancer

Quemliclustat has been granted an orphan drug designation in the U.S. as a potential treatment for pancreatic cancer. The U.S. Food and Drug Administration gives this designation to provide extra incentives for companies that are investing in developing treatments for rare diseases, or disorders that affect 200,000 or fewer people in the U.S. The companies are eligible for perks including tax breaks, fee waivers, and a guarantee of seven years m…